VERZENIO (abemaciclib)
TherapyEli Lilly
VERZENIO (abemaciclib) from Eli Lilly is a CDK4/6 inhibitor used in hormone receptor–positive breast cancer.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and VERZENIO. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where VERZENIO is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Breast Cancer Solid Tumor · Breast | Ki-67
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for VERZENIO.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering VERZENIO for eligible patients.
Test
Ki-67 IHC MIB-1 pharmDx
Dako Omnis (Agilent Technologies, Inc.)
1 approvalView test profile →